JP2022550734A5 - - Google Patents

Info

Publication number
JP2022550734A5
JP2022550734A5 JP2022519057A JP2022519057A JP2022550734A5 JP 2022550734 A5 JP2022550734 A5 JP 2022550734A5 JP 2022519057 A JP2022519057 A JP 2022519057A JP 2022519057 A JP2022519057 A JP 2022519057A JP 2022550734 A5 JP2022550734 A5 JP 2022550734A5
Authority
JP
Japan
Prior art keywords
svhd
patient
patients
vat
udenafil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022519057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550734A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/032493 external-priority patent/WO2021061203A1/en
Publication of JP2022550734A publication Critical patent/JP2022550734A/ja
Publication of JP2022550734A5 publication Critical patent/JP2022550734A5/ja
Priority to JP2025063654A priority Critical patent/JP2025118624A/ja
Pending legal-status Critical Current

Links

JP2022519057A 2019-09-24 2020-05-12 ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数（ｍｐｉ）を改善する方法 Pending JP2022550734A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025063654A JP2025118624A (ja) 2019-09-24 2025-04-08 ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数（ｍｐｉ）を改善する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962905350P 2019-09-24 2019-09-24
US62/905,350 2019-09-24
US201962936497P 2019-11-16 2019-11-16
US62/936,497 2019-11-16
US202063023070P 2020-05-11 2020-05-11
US63/023,070 2020-05-11
PCT/US2020/032493 WO2021061203A1 (en) 2019-09-24 2020-05-12 Methods of improving exercise performance, single ventricular performance, and myocardial performance index (mpi) in single ventricle heart disease, using udenafil compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025063654A Division JP2025118624A (ja) 2019-09-24 2025-04-08 ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数（ｍｐｉ）を改善する方法

Publications (2)

Publication Number Publication Date
JP2022550734A JP2022550734A (ja) 2022-12-05
JP2022550734A5 true JP2022550734A5 (cg-RX-API-DMAC10.html) 2023-06-07

Family

ID=75167062

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022519057A Pending JP2022550734A (ja) 2019-09-24 2020-05-12 ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数（ｍｐｉ）を改善する方法
JP2025063654A Pending JP2025118624A (ja) 2019-09-24 2025-04-08 ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数（ｍｐｉ）を改善する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025063654A Pending JP2025118624A (ja) 2019-09-24 2025-04-08 ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数（ｍｐｉ）を改善する方法

Country Status (7)

Country Link
US (1) US12576081B2 (cg-RX-API-DMAC10.html)
EP (1) EP4041242A4 (cg-RX-API-DMAC10.html)
JP (2) JP2022550734A (cg-RX-API-DMAC10.html)
AU (1) AU2020356193B2 (cg-RX-API-DMAC10.html)
CA (1) CA3155861A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022003593A (cg-RX-API-DMAC10.html)
WO (1) WO2021061203A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023009537A1 (en) * 2021-07-26 2023-02-02 Longeveron Inc. Use of mesenchymal stem cells in treatment of juvenile hypoplastic left heart syndrome
AU2022419178A1 (en) * 2021-12-20 2024-08-08 Mezzion Pharma Co., Ltd. Methods and compositions for improving exercise performance
EP4785873A1 (en) 2025-01-30 2026-08-05 SonoFit AS Wearable fitness devices and methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272741A1 (en) * 2004-01-16 2005-12-08 Jack Rychik Novel methods of treatment for Fontan patients with protein losing enteropathy
WO2005094521A2 (en) * 2004-03-23 2005-10-13 Georgia Tech Research Corporation Anatomical connection
EP1888074B1 (en) 2005-06-10 2011-12-21 Dong-A Pharmaceutical Co., Ltd. Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative
CA2623657A1 (en) 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
KR100792126B1 (ko) 2006-04-04 2008-01-04 동아제약주식회사 피라졸로피리미디논 화합물을 유효성분으로 함유하는전립선 비대증 예방 및 치료제
KR101002490B1 (ko) 2007-06-09 2010-12-17 동아제약주식회사 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물
JP2010532319A (ja) 2007-06-13 2010-10-07 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 聴覚障害の処置用のｐｄｅ阻害剤
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
KR101071877B1 (ko) 2009-02-18 2011-10-10 동아제약주식회사 유데나필 산부가염, 그의 제조방법 및 이를 포함하는 약학적 조성물
DK2512479T3 (en) 2009-12-18 2016-06-06 Exodos Life Sciences Ltd Partnership Compositions for the treatment of peripheral vascular disease
EP2556820A4 (en) 2010-04-05 2015-01-21 Sk Chemicals Co Ltd COMPOSITION CONTAINING PDE5 INHIBITOR FOR MITIGATION OF SKIN WRINKLES
JP5883687B2 (ja) 2011-03-09 2016-03-15 第一三共ヘルスケア株式会社 Ｐｄｅ５阻害剤含有医薬組成物
KR101383430B1 (ko) 2012-01-26 2014-04-08 광동제약 주식회사 새로운 조합의 구강내 속붕해 필름형성 조성물 및 ｐｄｅ５ 저해제가 함유된 구강내 속붕해 필름제제
BR112015010947A2 (en) 2012-11-13 2018-06-05 Nusirt Sciences, Inc. compositions and methods for increasing energy metabolism.
MX390977B (es) 2014-08-12 2025-03-21 Mezzion Pharma Co Ltd Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontan que utilizan composiciones de udenafilo

Similar Documents

Publication Publication Date Title
US5827893A (en) Mechanical and pharmacological therapies to treat cardiac arrest
FI4243825T3 (fi) Omekamtiivimekarbiili sydämen vajaatoiminnan hoitoon valikoiduilla potilasryhmillä
CN102056603A (zh) 决奈达隆用于预防持续性心房纤颤
JP2023540485A5 (cg-RX-API-DMAC10.html)
Chua et al. Novel use of sildenafil in the treatment of portopulmonary hypertension
JP2023116697A5 (cg-RX-API-DMAC10.html)
Varon et al. Cardiopulmonary resuscitation: a review for clinicians
COHEN et al. Adverse hemodynamic effects of phentolamine in primary pulmonary hypertension
JPS63141934A (ja) ディルチアゼムおよびアンギオテンシン変換酵素阻害剤を含有する医薬組成物
Galland et al. Swift recovery of severe hypoxemic pneumonia upon morbid obesity
CA3155861A1 (en) Methods of improving exercise performance, single ventricular performance, and myocardial performance index (mpi) in single ventricle heart disease, using udenafil compositions
Giacomini et al. Vardenafil and weaning from inhaled nitric oxide: effect on pulmonary hypertension in ARDS
Shocket et al. Successful open cardiac massage after 75 minutes of closed massage
Sinatra Refractory congestive heart failure successfully managed with high dose coenzyme Q10 administration
Mason et al. Combined use of hexamethonium bromide and procaine amide in controlled hypotension
RU2245147C2 (ru) Применение ингибитора вазопептидазы для лечения стенокардии
JP2004511433A (ja) 末梢血管疾患、末梢ニューロパシー、及び自律性ニューロパシーの処置方法
US20040176387A1 (en) Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies
JP2025504706A5 (cg-RX-API-DMAC10.html)
Evans et al. The effects of long term methyldopa in patients with hypoxic cor pulmonale
Galea et al. Sildenafil in acute pulmonary embolism: case report and review of literature
Hsu et al. Intrapericardial spontaneous contrast echoes in pneumopyopericardium due to a gas-forming organism
Shankar et al. Comparing effects of different levels of positive end-expiratory pressure on aeration score in laparoscopic surgeries using lung ultrasound: A randomised controlled trial
Odendaal Cardiopulmonary-cerebral resuscitation
Maki et al. Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension